-  Launched in 2020, JATENZO was the first oral softgel testosterone medicine approved in the US by the FDA in more than 60 years -  JATENZO is an oral softgel testosterone undecanoate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired) -  Compelling fit with Tolmar's strategy to acquire and develop therapies targeting diseases and conditions in Urology, Oncology and Orphan Diseases leveraging the company's focus and commitment in Urology community and Men's Health

BUFFALO GROVE, Ill. , Oct. 28, 2022 /PRNewswire/ -- Tolmar Pharmaceuticals, Inc., a fully integrated pharmaceutical company, through its affiliate, Tolmar, Inc., today announced the acquisition of all rights to JATENZO® from Clarus Therapeutics Holdings, Inc. (OTC: CRXTQ) and its wholly-owned subsidiary Clarus Therapeutics, Inc. (collectively, "Clarus"). Following a competitive auction process, Tolmar was selected as the winning bidder in the sale of JATENZO (and certain related assets), and the sale was approved by the U.S. Bankruptcy Court for the District of Delaware .

"The addition of JATENZO to Tolmar's robust portfolio further strengthens our position as a leader in urology and men's health," said Anil D'Souza, President and Chief Executive Officer of Tolmar Pharmaceuticals. " We have seen tremendous success in urology through our foundational therapy, ELIGARD®, a market-leading product for advanced prostate cancer. This acquisition advances Tolmar's overall business strategy, provides substantial growth potential and helps advance our mission to advocate for patients through our therapies. In addition, we are confident that adding JATENZO to the products promoted by our successful urology field sales force will lead to fast and more profitable growth for this differentiated product."

Todd Smith , President and Chief Commercial Officer, added, "Hypogonadism affects each man differently, and JATENZO expands treatment options for patients and HCPs by offering a differentiated alternative to existing testosterone replacement therapies. The acquisition of JATENZO is another milestone that solidifies Tolmar's commitment to bringing forward therapies that improve healthcare experience as well as disease outcomes."

JATENZO's proprietary formulation is built around testosterone undecanoate—a testosterone prodrug that the body converts to testosterone. In the JATENZO pivotal inTUne (investigational testosterone undecanoate) clinical trial, 87 percent of hypogonadal men treated with JATENZO achieved a mean total testosterone concentration in the eugonadal range at the end of treatmenti. The efficacy and safety of JATENZO was evaluated in 166 adult, hypogonadal males in a 4-month, open-label study. The primary endpoint was the percentage of patients with mean plasma total testosterone concentration (Cavg) over 24 hours within the normal eugonadal range on the final PK visit of the study.

RBC Capital Markets is acting as financial advisor and Faegre Drinker Biddle & Reath LLP is acting as legal advisor to Tolmar in connection with the transaction.

Tolmar Pharmaceuticals is a fully integrated pharmaceutical company focused on the innovative development, manufacturing, and commercialization of specialty pharmaceuticals across multiple therapeutic areas, including Urology. Tolmar global headquarters, product development and manufacturing facilities are based in Northern Colorado , while North America commercial headquarters is based in Buffalo Grove, Illinois . For more information about the company, please visit tolmar.com.

ELIGARD®, (leuprolide acetate) for injectable suspension, is indicated for the palliative treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported. See package insert for full Prescribing and Safety Information.

JATENZO® (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitation of use Safety and efficacy of JATENZO in males less than 18 years old have not been established.

WARNING: INCREASES IN BLOOD PRESSURE

JATENZO can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death. Before initiating JATENZO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled. Periodically monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension and re-evaluate whether the benefits of JATENZO outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease on treatment. Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies. CONTRAINDICATIONS JATENZO is contraindicated in men with breast cancer or known or suspected prostate cancer. JATENZO is contraindicated in women who are pregnant as testosterone may cause fetal harm.

Check hematocrit prior to initiation and every 3 months while a patient is on JATENZO and if hematocrit becomes elevated, stop JATENZO until hematocrit decreases to an acceptable level. If hematocrit increases after JATENZO is restarted, stop permanently. Monitor patients with benign prostatic hyperplasia (BPH) treated with androgens due to an increased risk for worsening signs and symptoms of BPH. Venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported in patients using testosterone replacement products like JATENZO. Evaluate patients with signs or symptoms consistent with DVT or PE and, if a VTE is suspected, discontinue JATENZO and initiate appropriate workup and management. Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Large doses of androgens can suppress spermatogenesis by feedback inhibition of pituitary FSH. Inform patients of this risk before prescribing JATENZO. Prolonged use of high doses of methyltestosterone has been associated with serious hepatic adverse events. JATENZO is not known to cause these adverse events; however, patients should be instructed to report any signs of hepatic dysfunction and JATENZO should be discontinued while the cause is evaluated. Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required. Gynecomastia may develop and persist in patients being treated for hypogonadism. Sleep apnea may occur in some patients, especially those with risk factors such as obesity or chronic lung disease. Changes in the serum lipid profile may require dose adjustment of lipid-lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically, particularly after starting testosterone therapy. Use JATENZO with caution in cancer patients at risk of hypercalcemia. Monitor serum calcium concentration regularly during treatment with JATENZO in these patients. Androgens, including JATENZO, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. Depression and suicidal ideation have been reported in patients treated with JATENZO in clinical trials.

ADVERSE EVENTS The most common adverse events of JATENZO (incidence ≥2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

These are not all of the risks associated with JATENZO. For more information, click here for full Prescribing Information, including BOXED WARNING on increases in blood pressure.

Company Contact: Tolmar Pharmaceuticals, Inc. Julie Ferguson Julie@jfprmedia.com 312-385-0098

View original content:https://www.prnewswire.com/news-releases/tolmar-announces-acquisition-of-jatenzo-testosterone-undecanoate-for-the-treatment-of-hypogonadism-to-expand-its-market-leading-urology-portfolio-301662003.html

New data reveals 1 in 3 Americans didn't discuss finances before marriage — and many wish they had.

Microsoft founder and billionaire turned philanthropist Bill Gates recently laid to rest the long-time conspiracy theory that he owns some 80% of all U.S. farmland in his 11th appearance in an “Ask Me Anything” (AMA) session on Reddit. What Happened: Gates, answering dozens of questions over the course of a few hours during the AMA, including: “Why are you buying up so much farmland, do you think this is a problem with billionaire wealth and how much you can disproportionally acquire?” In respon

(Bloomberg) -- Warren Buffett slashed his holding of Taiwan Semiconductor Manufacturing Co. just months after disclosing a major stake, an unusually quick reversal by the legendary stock picker that’s chilling investor sentiment toward the chip giant.Most Read from BloombergUS Says 3 Mystery Objects Likely Private, With No China LinkNew Cars Are Only for the Rich Now as Automakers Rake In ProfitsGunman Kills Three at Michigan State; Suspect Found DeadAmerica's Priciest Neighborhoods Are Changing

A new study looked at the prices at several fast-casual and fast-food chains, and at how diners feel about the value offered relative to cost.

(Bloomberg) -- Asset manager Vanguard Group plans to shutter a US mutual fund for the first time since the throes of the pandemic.Most Read from BloombergNew Cars Are Only for the Rich Now as Automakers Rake In ProfitsGunman Kills Three at Michigan State; Suspect Found DeadUS Says 3 Mystery Objects Likely Private, With No China LinkAmerica's Priciest Neighborhoods Are Changing as the Ultra-Rich Move to FloridaUS Inflation Stays Elevated, Adding Pressure for More Fed HikesThe $98 million Vanguard

The legendary financier continued to buy Tesla shares in the fourth quarter despite the electric vehicle maker's stock market rout.

Being patient doesn't always pay off.

Last year’s bearish trend has turned on a dime into 2023’s bull run, and the question now is, what next? One prominent name to wade in on the matter is billionaire Ken Fisher. With a history of decades-long investing success, Fisher knows a thing or two about market behavior. The Fisher Investments founder famously started his independent money management firm with just $250 in 1979, a company that is now a $197-plus billion going concern, while Fisher’s own net worth stands north of $5 billion.

Stocks moving in after-hours: Airbnb, TripAdvisor, Devon Energy

If you’re looking for certificates of deposit, the interest rates on offer should be—here’s hoping—heading higher following the latest inflation numbers out Tuesday morning. You can already get 5% on a one-year CD if you shop around, and there should be more—and maybe better—on offer soon following the latest economic news, which has sent the money markets jumping around. January’s inflation data came in higher than expected, and the markets were surprised by the news, even though Federal Reserve Chairman Jay Powell had basically told them this was going to happen at his press conference a couple of weeks ago.

You know it's time to be scared when a TikToker says so.

Devon Energy Corp (NYSE: DVN) shares are trading lower in Tuesday’s after-hours session after the company reported fourth-quarter results. What Happened: Devon Energy reported adjusted fourth-quarter earnings of $1.66 per share, which missed average analyst estimates of $1.75 per share, according to data from Benzinga Pro. Operating cash flow totaled $1.9 billion in the fourth quarter, up 18% year-over-year, resulting in $1.1 billion in free cash flow for the quarter. Devon Energy said productio

Berkshire Hathaway Inc. revealed several changes to its stock portfolio in documents filed with the Securities and Exchange Commission Tuesday. Many investors follow the company's moves closely because of Buffett's remarkably successful investing record over the decades. Berkshire picked up nearly 21 million more shares in the iPhone maker during the final three months of last year to give it 915.6 million shares at the end of 2022.

'For 14 of these years my fiancé worked many jobs, and always had payroll tax deductions, but chose not to file yearly income taxes'

Just because the S&P 500 index has leaped 8% so far this year doesn't mean that all stocks are overvalued.

U.S. real interest rates are at their highest point in 15 years -- typically a bullish environmnt for bonds.

My house is worth $450,000, with a loan balance of $248,000, which I had recently refinanced to a 3.35% mortgage rate. It is kind of you to give your daughter a financial leg-up by willing your home to her.

NIO Inc. (NIO) closed the most recent trading day at $10.31, making no change from the previous trading session.

The market is poised for the next metals and mining bull market to commence. The theme for the last bull market was centered on globalization and the emergence of a new middle class in what we defi...

Berkshire Hathaway, for the first time in years, neither added a brand new position nor fully liquidated an existing holding in the fourth quarter.